Managing Partner Michael Abrams spoke with PharmaVoice about President Trump’s recent drug pricing executive order and the impact of potential tariffs.

Whether any of the solutions generated are effective will depend on the creativity of those assigned to come up with potential solutions and the follow-through on those solutions deemed viable.

Abrams added that branded pharmaceuticals will be better positioned to absorb the costs of tariffs, noting generic manufacturer’s slim margins.

Read the full story at PharmaVoice.